title: Science to practice: Can we expand focal interventional oncologic ablation treatments into an effective systemic therapy?
abstract: Hamamoto et al (1) were able to demonstrate that combination therapy of a lung tumor by using radiofrequency ablation (RFA) with local injection of an immunostimulant, OK-432, resulted in improved survival when compared with other therapies tested in a VX2 rabbit model. In addition, not only was greater tumor regression seen in a second distant ear tumor implanted prior to the therapy, but also reduced tumor growth was seen when a second tumor implantation (ie, rechallenge) was attempted. These factors strongly suggest the successful activation of systemic antitumor immunity using this approach in this specific tumor model.
authors.affiliation: Image-guided Therapy and Interventional Oncology Unit Department of Radiology Hadassah Hebrew University Medical Center, Ein Karem, Jerusalem, Israel.
authors.forename: S Nahum
authors.initials: SN
authors.lastname: Goldberg
mesh_terms: D000818:Animals; D017115:Catheter Ablation; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D010844:Picibanil / Q000494:pharmacology*
chemical_list: D010844:Picibanil